Faculty
Oncology Division
Alphabetical list (active faculty):   
Joel Picus

Joel Picus, MD

Professor

Department of Medicine

Oncology Division

Medical Oncology

Research Interests

  • Clinical cancer research
  • Prostate cancer
  • Pancreatic cancer
  • Biliary cancer
  • Colorectal cancer

Contact

  • 314-362-5740 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Articles

  • Vorolanib (X-82), an Oral Anti-VEGFR/PDGFR/CSF1R Tyrosine Kinase Inhibitor, With Everolimus in Solid Tumors: Results of a Phase I Study
    Pedersen KS, Grierson PM, Picus J, Lockhart AC, Roth BJ, Liu J, Morton A, Chan E, Huffman J, Liang C, Wang-Gillam A, Tan B
    Invest New Drugs 2021 Oct;39(5):1298-1305
  • Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors
    Amin M, Gao F, Terrero G, Picus J, Wang-Gillam A, Suresh R, Ma C, Tan B, Baggstrom M, Naughton MJ, Trull L, Belanger S, Fracasso PM, Lockhart AC
    Am J Clin Oncol 2021 Sep 1;44(9):443-448
  • Phase 1 Study Combining Alisertib With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
    Lim KH, Opyrchal M, Acharya A, Boice N, Wu N, Gao F, Webster J, Lockhart AC, Waqar SN, Govindan R, Morgensztern D, Picus J, Tan BR, Baggstrom MQ, Maher CA, Wang-Gillam A
    Eur J Cancer 2021 Sep;154:102-110
  • Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
    Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ
    J Clin Oncol 2021 Aug 1;39(22):2486-2496
  • Angiokines Associated With Targeted Therapy Outcomes in Patients With Non-Clear Cell Renal Cell Carcinoma
    Armstrong AJ, Nixon AB, Carmack A, Yang Q, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, George DJ, Halabi S
    Clin Cancer Res 2021 Jun 15;27(12):3317-3328
  • Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy
    Fischer-Valuck BW, Michalski JM, Harton JG, Birtle A, Christodouleas JP, Efstathiou JA, Arora VK, Kim EH, Knoche EM, Pachynski RK, Picus J, Rao YJ, Reimers M, Roth BJ, Sargos P, Smith ZL, Zaghloul MS, Gay HA, Patel SA, Baumann BC
    Clin Genitourin Cancer 2021 Feb;19(1):41-46
  • Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
    Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, Gupta S, Davis N, Picus J, Philips G, Quinn DI, Haines GK 3rd, Hahn NM, Zhao Q, Yu M, Pal SK
    J Clin Oncol 2020 Jun 1;38(16):1797-1806
  • Pemphigus Foliaceus in a Patient With Gastrointestinal Stromal Tumor Treated With Adjuvant Imatinib Mesylate
    Lewis HA, Chen DY, Rosman IS, Picus J, Anadkat MJ
    Dermatol Online J 2020 Jun 15;26(6)
  • Cell-Free DNA Alterations in the AR Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer
    Dang HX, Chauhan PS, Ellis H, Feng W, Harris PK, Smith G, Qiao M, Dienstbach K, Beck R, Atkocius A, Qaium F, Luo J, Michalski JM, Picus J, Pachynski RK, Maher CA, Chaudhuri AA
    JCO Precis Oncol 2020;4:680-713
  • Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
    Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA
    J Natl Compr Canc Netw 2019 Dec;17(12):1529-1554
  • Pharmacodynamic and Clinical Results From a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination With Abiraterone Acetate in Prostate Cancer
    Slovin S, Hussain S, Saad F, Garcia J, Picus J, Ferraldeschi R, Crespo M, Flohr P, Riisnaes R, Lin C, Keer H, Oganesian A, Workman P, de Bono J
    Clin Cancer Res 2019 Aug 1;25(15):4624-4633
  • Phase II Trial of Levocetirizine With Capecitabine and Bevacizumab to Overcome the Resistance of Antiangiogenic Therapies in Refractory Metastatic Colorectal Cancer
    Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC
    J Gastrointest Oncol 2019 Jun;10(3):412-420
  • Cabozantinib Versus Sunitinib for Untreated Patients With Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN Trial
    George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK
    Oncologist 2019 Nov;24(11):1497-1501
  • Mocetinostat for Patients With Previously Treated, Locally Advanced/Metastatic Urothelial Carcinoma and Inactivating Alterations of Acetyltransferase Genes
    Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE
    Cancer 2019 Feb 15;125(4):533-540
  • A Propensity Analysis Comparing Definitive Chemo-Radiotherapy for Muscle-Invasive Squamous Cell Carcinoma of the Bladder Vs. Urothelial Carcinoma of the Bladder Using the National Cancer Database
    Fischer-Valuck BW, Michalski JM, Contreras JA, Brenneman R, Christodouleas JP, Abraham CD, Kim EH, Arora VK, Bullock AD, Carmona R, Figenshau RS, Grubb R 3rd, Knoche EM, Pachynski RK, Picus J, Roth BJ, Sargos P, Andriole GL, Gay HA, Baumann BC
    Clin Transl Radiat Oncol 2018 Dec 12;15:38-41
  • Corrigendum to 'Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update' [Eur J Cancer 94 (May 2018) 115-125]
    Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ
    Eur J Cancer 2018 Nov;103:287
  • Apatorsen Plus Docetaxel Versus Docetaxel Alone in Platinum-Resistant Metastatic Urothelial Carcinoma (Borealis-2)
    Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK
    Br J Cancer 2018 May;118(11):1434-1441
  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
    Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ
    J Clin Oncol 2018 Apr 10;36(11):1080-1087
  • Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit From Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
    Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C
    Eur Urol 2018 Jun;73(6):847-855
  • Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update
    Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ
    Eur J Cancer 2018 May;94:115-125
  • Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
    Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ
    ECOG-ACRIN 3805 Investigators

    J Clin Oncol 2018 Feb 1;36(4):376-382
  • Combination Epigenetic Therapy in Metastatic Colorectal Cancer (MCRC) With Subcutaneous 5-Azacitidine and Entinostat: A Phase 2 Consortium/Stand Up 2 Cancer Study
    Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N
    Oncotarget 2017 May 23;8(21):35326-35338
  • Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
    Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ
    J Clin Oncol 2017 Feb 20;35(6):591-597
  • Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonist + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5-Day Cisplatin-Based Chemotherapy: A Hoosier Cancer Research Network Study
    Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z, Fausel CA, Breen T, Hanna NH, Hauke RJ, Picus J, Einhorn LH
    Support Care Cancer 2016 Jul;24(7):2837-42
  • Phase 1 Evaluation of [Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects With Advanced Solid Tumors
    Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Frye J, Trull L, Belanger S, Desai M, Mahmood S, Mendell J, Welch MJ, Siegel BA
    Mol Imaging Biol 2016 Jun;18(3):446-453
  • Everolimus Versus Sunitinib for Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN): A Multicentre, Open-Label, Randomised Phase 2 Trial
    Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ
    Lancet Oncol 2016 Mar;17(3):378-88
  • Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS
    N Engl J Med 2015 Aug 20;373(8):737-46
  • A Phase II Study of Adjuvant Gemcitabine Plus Docetaxel Followed by Concurrent Chemoradation in Resected Pancreaticobiliary Carcinoma
    Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR
    HPB (Oxford) 2015 Jul;17(7):587-93
  • Safety and Activity of Temsirolimus and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Previously Treated With Tyrosine Kinase Inhibitors: A Phase 2 Consortium Study
    Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C
    Cancer Chemother Pharmacol 2015 Mar;75(3):485-93
  • Thymidylate Synthase Genotype-Directed Chemotherapy for Patients With Gastric and Gastroesophageal Junction Cancers
    Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC
    PLoS One 2014 Sep 18;9(9):e107424
  • A Phase I Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Refractory Solid Malignancies
    Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J
    Cancer Chemother Pharmacol 2014 Aug;74(2):419-26
  • Five Fractions of Radiation Therapy Followed by 4 Cycles of FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
    Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh P
    Int J Radiat Oncol Biol Phys 2014 Mar 15;88(4):829-36
  • Effect of Abiraterone Acetate Treatment on the Quality of Life of Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of Docetaxel Chemotherapy
    Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI
    COU-AA-301 Investigators (Contributors include: Picus J)

    Eur J Cancer 2013 Nov;49(17):3648-57
  • A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
    Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U
    Clin Genitourin Cancer 2013 Dec;11(4):477-83
  • A Phase 2 Study of Intravenous Panobinostat in Patients With Castration-Resistant Prostate Cancer
    Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, Allen-Freda E, Mishra KK, Porro MG, Scher HI, Wilding G
    Cancer Chemother Pharmacol 2013 Sep;72(3):537-44
  • A Phase I Study of IMP321 and Gemcitabine as the Front-Line Therapy in Patients With Advanced Pancreatic Adenocarcinoma
    Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG
    Invest New Drugs 2013 Jun;31(3):707-13
  • Relationship Among Circulating Tumor Cells, CEA and Overall Survival in Patients With Metastatic Colorectal Cancer
    Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Cohen SJ
    Ann Oncol 2013 Feb;24(2):420-8
  • A Phase II Study of UCN-01 in Combination With Irinotecan in Patients With Metastatic Triple Negative Breast Cancer
    Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Lockhart AC, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM
    Breast Cancer Res Treat 2013 Jan;137(2):483-92
  • Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis With Rilotumumab Plus Mitoxantrone and Prednisone
    Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR
    Clin Cancer Res 2013 Jan 1;19(1):215-224
  • Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
    Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC
    J Clin Oncol 2012 Sep 20;30(27):3361-7
  • Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study
    Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS
    COU-AA-301 Investigators (Contributors include: Picus J)

    Lancet Oncol 2012 Oct;13(10):983-92
  • Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study
    Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH
    J Clin Oncol 2012 Nov 10;30(32):3998-4003
  • Efficacy of Peripheral Androgen Blockade in Prostate Cancer Patients With Biochemical Failure After Definitive Local Therapy: Results of Cancer and Leukemia Group B (CALGB) 9782
    Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ
    Cancer 2012 Sep 1;118(17):4139-4147
  • Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101
    Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ
    Oncologist 2012;17(1):13
  • Multi-Institutional Experience With FOLFIRINOX in Pancreatic Adenocarcinoma
    Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A
    JOP 2012 Sep 10;13(5):497-501
  • Increased Survival With Enzalutamide in Prostate Cancer After Chemotherapy
    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS
    AFFIRM Investigators (Contributors include: Picus J)

    N Engl J Med 2012 Sep 27;367(13):1187-97
  • An International, Multicenter Phase II Trial of Bortezomib in Patients With Hepatocellular Carcinoma
    Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J, Philip PA, Nowak A, Wright JJ, Erlichman C
    Invest New Drugs 2012 Feb;30(1):387-94
  • Biomarker-Driven Trial in Metastatic Pancreas Cancer: Feasibility in a Multicenter Study of Saracatinib, an Oral Src Inhibitor, in Previously Treated Pancreatic Cancer
    Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA
    Cancer Med 2012 Oct;1(2):207-17
  • Phase 2 Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer
    Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C
    Cancer 2012 May 1;118(9):2424-30
  • A Phase 2 Study of Estramustine, Docetaxel, and Bevacizumab in Men With Castrate-Resistant Prostate Cancer: Results From Cancer and Leukemia Group B Study 90006
    Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ
    Cancer 2011 Feb 1;117(3):526-33
  • A Phase 1 Study of UCN-01 in Combination With Irinotecan in Patients With Resistant Solid Tumor Malignancies
    Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H
    Cancer Chemother Pharmacol 2011 Jun;67(6):1225-37
  • A USA Registry of Gastrointestinal Stromal Tumor Patients: Changes in Practice Over Time and Differences Between Community and Academic Practices
    Pisters PW, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC
    Ann Oncol 2011 Nov;22(11):2523-2529
  • Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab as First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
    Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ
    J Clin Oncol 2011 Apr 20;29(12):1525-1530
  • Abiraterone and Increased Survival in Metastatic Prostate Cancer
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fl├ęchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI
    COU-AA-301 Investigators (Contributors include: Picus J)

    N Engl J Med 2011 May 26;364(21):1995-2005
  • Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors
    Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J
    J Hematol Oncol 2011 Jun 14;4(1):29
  • A Phase 1, Multicenter, Open-Label Study of the Safety of Two Dose Levels of a Human Monoclonal Antibody to Human Alpha(V) Integrins, Intetumumab, in Combination With Docetaxel and Prednisone in Patients With Castrate-Resistant Metastatic Prostate Cancer
    Chu FM, Picus J, Fracasso PM, Dreicer R, Lang Z, Foster B
    Invest New Drugs 2011 Aug;29(4):674-9
  • Cardiac Tamponade or Hemopericardium Are Not Associated With Bleeding Risk Factors in Consecutive Patients Hospitalized With Noniatrogenic, Pericardial Effusions
    Faller BA, Zhang Q, Picus J
    Am J Hematol 2010 Apr;85(4):300-1
  • Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
    Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ
    J Clin Oncol 2010 May 1;28(13):2137-43
  • Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL
    J Clin Oncol 2010 Jul 1;28(19):3167-75
  • Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
    Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD
    J Clin Oncol 2010 Jul 20;28(21):3491-7
  • Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
    Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM
    J Clin Oncol 2010 Aug 1;28(22):3617-22
  • Gemcitabine With Carboplatin for Advanced Biliary Tract Cancers: A Phase II Single Institution Study
    Williams KJ, Picus J, Trinkhaus K, Fournier CC, Suresh R, James JS, Tan BR
    HPB (Oxford) 2010 Aug;12(6):418-26
  • Radiotherapy for Epidermoid Carcinoma of the Anus: Thirty Years' Experience
    Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR
    Int J Radiat Oncol Biol Phys 2009 Oct 1;75(2):428-35
  • Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ
    Ann Oncol 2009 Jul;20(7):1223-9
  • Sunitinib Treatment in Pediatric Patients With Advanced GIST Following Failure of Imatinib
    Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD
    Pediatr Blood Cancer 2009 Jul;52(7):767-71
  • A Phase II Study of Pegylated-Camptothecin (Pegamotecan) in the Treatment of Locally Advanced and Metastatic Gastric and Gastro-Oesophageal Junction Adenocarcinoma
    Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR
    Cancer Chemother Pharmacol 2009 Jan;63(2):363-70
  • Phase 1 and Pharmacokinetic Study of Weekly Docosahexaenoic Acid-Paclitaxel, Taxoprexin, in Resistant Solid Tumor Malignancies
    Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE
    Cancer Chemother Pharmacol 2009 Feb;63(3):451-8
  • Phase I Study of Biweekly Oxaliplatin, Gemcitabine and Capecitabine in Patients With Advanced Upper Gastrointestinal Malignancies
    Tan BR, Brenner WS, Picus J, Marsh S, Gao F, Fournier C, Fracasso PM, James J, Yen-Revollo JL, McLeod HL
    Ann Oncol 2008 Oct;19(10):1742-8
  • Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
    Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ
    J Clin Oncol 2008 Nov 20;26(33):5422-5428
  • A Phase II Study of Milataxel: A Novel Taxane Analogue in Previously Treated Patients With Advanced Colorectal Cancer
    Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, Hochster H, Cohn A
    Cancer Chemother Pharmacol 2008 Mar;61(3):453-8
  • Adjuvant Interferon-Based Chemoradiation Followed by Gemcitabine for Resected Pancreatic Adenocarcinoma: A Single-Institution Phase II Study
    Linehan DC, Tan MC, Strasberg SM, Drebin JA, Hawkins WG, Picus J, Myerson RJ, Malyapa RS, Hull M, Trinkaus K, Tan BR Jr
    Ann Surg 2008 Aug;248(2):145-51
  • Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
    Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS
    J Clin Oncol 2008 Jul 10;26(20):3403-10
  • Tumor Hypoxia Detected by Positron Emission Tomography With 60Cu-ATSM as a Predictor of Response and Survival in Patients Undergoing Neoadjuvant Chemoradiotherapy for Rectal Carcinoma: A Pilot Study
    Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA
    Dis Colon Rectum 2008 Nov;51(11):1641-8
  • Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ
    J Clin Oncol 2008 Jul 1;26(19):3213-21
  • Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study
    Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA
    J Urol 2007 May;177(5):1777-81
  • Long-Term Outcome After Chemoembolization and Embolization of Hepatic Metastatic Lesions From Neuroendocrine Tumors
    Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, Brown DB
    AJR Am J Roentgenol 2007 May;188(5):1201-7
  • Phase II Study of KOS-862 in Patients With Metastatic Androgen Independent Prostate Cancer Previously Treated With Docetaxel
    Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL
    Invest New Drugs 2007 Dec;25(6):565-70
  • A Phase II Study of Gemcitabine and Capecitabine in Metastatic Renal Cancer: A Report of Cancer and Leukemia Group B Protocol 90008
    Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ
    Cancer 2006 Sep 15;107(6):1273-9
  • The Role of Primary Chemotherapy for Prostate Cancer: Has the Time Come?
    Hruska PP, Picus J
    Curr Urol Rep 2006 May;7(3):233-8
  • Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
    Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C
    J Clin Oncol 2006 Jul 1;24(19):3069-74
  • Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients With Metastatic Hormone- Refractory Prostate Cancer: Results From Cancer and Leukemia Group B 150005/9480
    Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW
    Clin Genitourin Cancer 2006 Mar;4(4):269-74
  • Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
    Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C
    J Clin Oncol 2005 Sep 20;23(27):6657-63
  • A Phase II Study of Alternating Cycles of Split Course Radiation Therapy and Gemcitabine Chemotherapy for Inoperable Pancreatic or Biliary Tract Carcinoma
    Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM, Tan B, Thorstad WL, Myerson R
    Am J Clin Oncol 2005 Jun;28(3):234-41
  • Phase I Study of Pegylated Liposomal Doxorubicin and the Multidrug-Resistance Modulator, Valspodar
    Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL
    Br J Cancer 2005 Jul 11;93(1):46-53
  • Positron Tomographic Assessment of Androgen Receptors in Prostatic Carcinoma
    Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, Welch MJ
    Eur J Nucl Med Mol Imaging 2005 Mar;32(3):344-50
  • Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy
    David KA, Picus J
    Am J Clin Oncol 2005 Jun;28(3):277-80
  • Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)
    Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ
    J Clin Oncol 2004 Mar 15;22(6):1025-33
  • Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663
    Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ
    J Clin Oncol 2003 Jul 15;21(14):2673-8
  • Phase II Study of Gemcitabine Plus Docetaxel in Advanced Pancreatic Cancer: A Hoosier Oncology Group Study
    Schneider BP, Ganjoo KN, Seitz DE, Picus J, Fata F, Stoner C, Calley C, Loehrer PJ
    Oncology 2003;65(3):218-23
  • 11C-Acetate PET Imaging of Prostate Cancer: Detection of Recurrent Disease at PSA Relapse
    Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J, Welch MJ
    J Nucl Med 2003 Apr;44(4):549-55
  • CDKN1A and CDKN1B Polymorphisms and Risk of Advanced Prostate Carcinoma
    Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J, Goodfellow PJ
    Cancer Res 2003 May 1;63(9):2033-6
  • Phase I Dose and Sequencing Study of Pegylated Liposomal Doxorubicin and Docetaxel in Patients With Advanced Malignancies
    Fracasso PM, Rodriguez LC, Herzog TJ, Fears CL, Goodner SA, Govindan R, Picus J, Rader JS, Tan BR, Arquette MA
    Cancer 2003 Aug 1;98(3):610-7
  • The Addition of Continuous Infusion 5-FU to Preoperative Radiation Therapy Increases Tumor Response, Leading to Increased Sphincter Preservation in Locally Advanced Rectal Cancer
    Crane CH, Skibber JM, Birnbaum EH, Feig BW, Singh AK, Delclos ME, Lin EH, Fleshman JW, Thames HD, Kodner IJ, Lockett MA, Picus J, Phan T, Chandra A, Janjan NA, Read TE, Myerson RJ
    Int J Radiat Oncol Biol Phys 2003 Sep 1;57(1):84-9
  • A Phase II Hoosier Oncology Group Study of Vinorelbine and Estramustine Phosphate in Hormone-Refractory Prostate Cancer
    Sweeney CJ, Monaco FJ, Jung SH, Wasielewski MJ, Picus J, Ansari RH, Dugan WM, Einhorn LH
    Ann Oncol 2002 Mar;13(3):435-40
  • Severe Interstitial Pneumonitis Associated With Docetaxel Administration
    Read WL, Mortimer JE, Picus J
    Cancer 2002 Feb 1;94(3):847-53
  • Early Results From a Phase I/II Radiation Dose-Escalation Study With Concurrent Amifostine and Infusional 5-Fluorouracil Chemotherapy for Preoperative Treatment of Unresectable or Locally Recurrent Rectal Carcinoma
    Myerson R, Zobeiri I, Birnbaum E, Dietz D, Fleshman J, Kodner I, Picus J, Ratkin G
    Semin Oncol 2002 Dec;29(6 Suppl 19):29-33
  • Advanced Prostate Cancer: A State-Of-The-Art Guide to Pharmacological Management
    Naughton M, Picus J
    Am J Cancer 2002;1:13-22
  • Phase I Study of Rubitecan and Gemcitabine in Patients With Advanced Malignancies
    Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL
    Ann Oncol 2002 Nov;13(11):1819-25
  • Altretamine for the Treatment of Metastatic Renal Cell Carcinoma. A Hoosier Oncology Group Trial
    Zon RT, McClean J, Helman D, Ansari R, Picus J, Sandler A, Williams SD, Loehrer PJ Sr
    Invest New Drugs 2001;19(3):229-31
  • Neoadjuvant Therapy for Adenocarcinoma of the Rectum: Tumor Response and Acute Toxicity
    Read TE, McNevin MS, Gross EK, Whiteford HM, Lewis JL, Ratkin G, Picus J, Birnbaum EH, Fleshman JW, Kodner IJ, Myerson RJ
    Dis Colon Rectum 2001 Apr;44(4):513-22
  • Scatter Factor-Hepatocyte Growth Factor Elevation in the Serum of Patients With Prostate Cancer
    Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA
    J Urol 2001 Apr;165(4):1325-8
  • A Phase I/II Trial of Three-Dimensionally Planned Concurrent Boost Radiotherapy and Protracted Venous Infusion of 5-FU Chemotherapy for Locally Advanced Rectal Carcinoma
    Myerson RJ, Valentini V, Birnbaum EH, Cellini N, Coco C, Fleshman JW, Gambacorta MA, Genovesi D, Kodner IJ, Picus J, Ratkin GA, Read TE
    Int J Radiat Oncol Biol Phys 2001 Aug 1;50(5):1299-308
  • Pretreatment Clinical Findings Predict Outcome for Patients Receiving Preoperative Radiation for Rectal Cancer
    Myerson RJ, Singh A, Birnbaum EH, Fry RD, Fleshman JW, Kodner IJ, Lockett MA, Picus J, Walz BJ, Read TE
    Int J Radiat Oncol Biol Phys 2001 Jul 1;50(3):665-74
  • Radiation Therapy for Epidermoid Carcinoma of the Anal Canal, Clinical and Treatment Factors Associated With Outcome
    Myerson RJ, Kong F, Birnbaum EH, Fleshman JW, Kodner IJ, Picus J, Ratkin GA, Read TE, Walz BJ
    Radiother Oncol 2001 Oct;61(1):15-22
  • Phase II Study of the Multitargeted Antifolate LY231514 (ALIMTA, MTA, Pemetrexed Disodium) in Patients With Advanced Pancreatic Cancer
    Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton D, Rowinsky E, Loehrer PJ Sr
    Ann Oncol 2000 Jan;11(1):101-3
  • Activity of Multitargeted Antifolate (Pemetrexed Disodium, LY231514) in Patients With Advanced Colorectal Carcinoma: Results From a Phase II Study
    John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK, Thornton DE, Loehrer PJ
    Cancer 2000 Apr 15;88(8):1807-13
  • Docetaxel (Taxotere) as Monotherapy in the Treatment of Hormone-Refractory Prostate Cancer: Preliminary Results
    Picus J, Schultz M
    Semin Oncol 1999 Oct;26(5 Suppl 17):14-8
  • Five Fractions of Preoperative Radiotherapy for Selected Cases of Rectal Carcinoma: Long-Term Tumor Control and Tolerance to Treatment
    Myerson RJ, Genovesi D, Lockett MA, Birnbaum E, Fleshman J, Fry R, Kodner I, Menteer J, Picus J, Read T, Walz B
    Int J Radiat Oncol Biol Phys 1999 Feb 1;43(3):537-43
  • Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
    Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ
    J Clin Oncol 1999 Aug;17(8):2506-13
  • Interventional Radiologic Placement of Hohn Central Venous Catheters: Results and Complications in 100 Consecutive Patients
    Openshaw KL, Picus D, Hicks ME, Darcy MD, Vesely TM, Picus J
    J Vasc Interv Radiol 1994 Jan-Feb;5(1):111-5
  • Multidisciplinary Treatment of Biliary Tract Cancers
    Kraybill WG, Lee H, Picus J, Ramachandran G, Lopez MJ, Kucik N, Myerson RJ
    J Surg Oncol 1994 Apr;55(4):239-45
  • The Regulation of T-Cell Antigen Receptor Signal Transduction Function
    Weiss A, Desai D, Graber M, Picus J, Koretzky G
    Transplant Proc 1991 Feb;23(1 Pt 1):32-3
  • Tyrosine Phosphatase CD45 Is Required for T-Cell Antigen Receptor and CD2-Mediated Activation of a Protein Tyrosine Kinase and Interleukin 2 Production
    Koretzky GA, Picus J, Schultz T, Weiss A
    Proc Natl Acad Sci U S A 1991 Mar 15;88(6):2037-41
  • Tyrosine Phosphatase CD45 Is Essential for Coupling T-Cell Antigen Receptor to the Phosphatidyl Inositol Pathway
    Koretzky GA, Picus J, Thomas ML, Weiss A
    Nature 1990 Jul 5;346(6279):66-8
  • A Naturally Occurring Bone Marrow-Chimeric Primate. II. Environment Dictates Restriction on Cytolytic T Lymphocyte-Target Cell Interactions
    Picus J, Holley K, Aldrich WR, Griffin JD, Letvin NL
    J Exp Med 1985 Dec 1;162(6):2035-52
  • A Naturally Occurring Bone-Marrow-Chimeric Primate. I. Integrity of Its Immune System
    Picus J, Aldrich WR, Letvin NL
    Transplantation 1985 Mar;39(3):297-303
  • Immunologic Effects of Whole-Body Ultraviolet (Uv) Irradiation. III Defective Splenic Adherent Cell Function in Alloantigen-Stimulated T- Cell Proliferation
    Picus J, Germain RN, Fox IJ, Greene MI, Benacerraf B, Letvin NL
    Cell Immunol 1981 Sep 15;63(2):300-7
  • Studies on Total Population of Poly-Adenylated RNAs From Soybean Hypocotyl
    Shafer TH, Picus J, Vanderhoef LN
    Plant Physiol 1978;61:62

Book Chapters

  • Gastrointestinal Complications of Chemotherapy
    Picus J, Martin MG
    In: The Chemotherapy Source Book, 4th Edition, 2008, pp 197-209
  • Principles of Radiation Therapy and Chemotherapy
    Myerson RJ, Picus J
    In: Gastrointestinal Cancers, Sanders, 2003, pp 175-185
  • Cancer of the Biliary Tree
    Lillemoe KD, Schulick RD, Kennedy AS, Picus J
    In: Clinical Management in Gastrointestinal Oncology: Principles and Practice, Lippincott, Williams and Wilkens, 2002, pp 645-652
  • Combining Chemotherapy With Radiation in the Adjuvant Care of Rectal Cancer: Morbidity of Treatment and Its Impact on Management Decisions
    Myerson RJ, Picus J, Read TE
    Perspectives in Colon and Rectal Surgery 2000;12:113-31
  • Somatic Cell Genetic Approach to Understanding T Cell Antigen Receptor Signal Transduction
    Koretzky GA, Goldsmith MA, Graber M, Picus J, Weiss A
    In: Genetic Approaches to Understanding Cell Activation, Raven Press, New York, NY, 1991